Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IONS vs PTGX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PTGX Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–1 Matrix Metrics)

PTGX Overall Winner 6-Pillar Tally: IONS 1 – 5 PTGX Matrix Metrics: IONS 1 – 9 PTGX

As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTGX carries 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin).

  • Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -58.8% operating margin) and revenue trajectory (+5723.6% vs. +54.9% YoY).
  • Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IONS vs PTGX
IONS NASDAQ
Ionis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$28.57
-1.7% 1D
Market Cap $4.7B
TTM Revenue $960M
Forward P/E 90.9x
Beta / 30D Vol 0.18β · 86% Vol
Unified Composite Score
63.9 / 100 BUY
Tech 60.0 Fund 63.0 Flow 73.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -16.3%), weak momentum, RSI 24
RSI-14: 23.7 · SMA20: $38.46 · SMA50: $43.07
PTGX NASDAQ Head-to-Head Winner
Protagonist Therapeutics, Inc
Pharmaceutical Preparations
$125.40
-4.24% 1D
Market Cap $8.7B
TTM Revenue $552M
Forward P/E 36.9x
Beta / 30D Vol 1.02β · 35% Vol
Unified Composite Score
32.6 / 100 SELL
Tech 17.0 Fund 44.0 Flow 67.0 Mom 60.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -3.6%), weak momentum, RSI 33
RSI-14: 33.0 · SMA20: $137.74 · SMA50: $139.89

6-Pillar Scorecard Institutional Category Breakdown (IONS 1 – 5 PTGX)

Columns: Metric · IONS · PTGX
1. Valuation Multiples PTGX
Forward P/E 90.9x 36.9x
Trailing P/E 90.9x 28.1x
PEG Ratio N/M N/M
EV / Revenue 6.2x 14.8x
2. Growth & Scale PTGX
Revenue Growth (YoY) +54.9% +5723.6%
Earnings Growth (YoY) -43.7% +351.3%
TTM Revenue (USD) $960M $552M
Market Cap $4.7B $8.7B
3. Profitability & Quality PTGX
Gross Margin 3.0% 99.8%
Operating Margin -58.8% 58.6%
Net Profit Margin -56.9% 62.0%
Return on Equity (ROE) -108.0% 39.6%
4. Balance Sheet & Cash Flow PTGX
Cash Generation (TTM) -$623M $109M
Cash Flow Margin -64.9% 19.8%
Net Cash / Leverage $1.33B Net Debt (4.14x D/E) $490M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning PTGX
Options Structure Phase BREAKDOWN CONSOLIDATION
Current IV / %ile 59.9% (17th %ile) 39.4% (3rd %ile)
Put/Call OI Skew 1.81x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IONS
OpEx & R&D Intensity 61.8% of Rev ($593M) 41.2% of Rev ($227M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IONS (1) vs PTGX (9)
Institutional Metric IONS PTGX Criterion Row Edge
Market Capitalization
Scale
$4.7B $8.7B Larger Scale PTGX
Trailing P/E Ratio
Valuation
90.9x 28.1x Lower Multiple PTGX
Forward P/E Ratio
Valuation
90.9x 36.9x Lower Multiple PTGX
Revenue Growth (YoY)
Growth
+54.9% +5723.6% Higher Growth PTGX
Operating Margin (TTM)
Profitability
-58.8% 58.6% Higher Margin PTGX
Net Profit Margin
Profitability
-56.9% 62.0% Higher Margin PTGX
Return on Equity (ROE)
Capital Efficiency
-108.0% 39.6% Higher ROE PTGX
52-Week Range Position
Momentum
2% ($27–$87) 58% ($77–$161) Stronger Trend PTGX
Beta / 30D Volatility
Risk Regime
0.18β · 86% Vol 1.02β · 35% Vol Lower Realized Risk PTGX
Unified Institutional Score
Composite Signal
63.9 / 100 (BUY) 32.6 / 100 (SELL) Higher Composite IONS
Trailing 12M Revenue (USD)
Operating Scale
$960M $552M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
3.0% 99.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.2x EV/Rev N/M PEG · 14.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$623M ($1.33B Net Debt (4.14x D/E)) $109M ($490M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PTGX +30.88 pp
IONS: -33.48% · PTGX: -2.6%
3M Horizon PTGX +31.79 pp
IONS: -52.09% · PTGX: -20.3%
6M Horizon PTGX +85.09 pp
IONS: -60.61% · PTGX: +24.48%
1Y Horizon PTGX +109.75 pp
IONS: -59.1% · PTGX: +50.65%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IONS Revenue PTGX Revenue IONS Op. Margin PTGX Op. Margin Margin Leader
FY2018 $600M $30M -10.2% -136.7% IONS
FY2019 $1.12B $0M 32.6% -34857.6% IONS
FY2020 $730M $30M -23.6% -225.4% IONS
FY2021 $810M $30M -3.7% -460.0% IONS
FY2022 $590M $30M -69.8% -494.2% IONS
FY2023 $790M $60M -44.9% -156.1% IONS
FY2024 $710M $430M -67.4% 58.2% PTGX
FY2025 $940M $50M -40.4% -343.6% IONS

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IONS BREAKDOWN
58d in phase · OBV DISTRIBUTION
Current IV 59.9%
IV Percentile 17th %ile
Put/Call OI Skew 1.81x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact IONS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PTGX CONSOLIDATION
64d in phase · OBV NEUTRAL
Current IV 39.4%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact PTGX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IONS Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $4.7B market capitalization and -58.8% operating margin.
OpEx & R&D Reinvestment 61.8% of Rev ($593M)
90D Engineering Disclosures 0 Published
PTGX Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $8.7B market capitalization and 58.6% operating margin.
OpEx & R&D Reinvestment 41.2% of Rev ($227M)
90D Engineering Disclosures 0 Published

Investor FAQ IONS vs PTGX Key Questions & Quantitative Answers

As of Nov 16, 2026, Protagonist Therapeutics, Inc (PTGX) is the stronger overall head-to-head candidate over Ionis Pharmaceuticals, Inc. (IONS) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IONS carries a Unified Composite Score of 63.9/100 (BUY) at $28.57 (90.9x Forward P/E, -58.8% operating margin), whereas PTGX carries 32.6/100 (SELL) at $125.40 (36.9x Forward P/E, 58.6% operating margin). Composite vs. Pillar Nuance: While IONS currently prints a higher short-term Unified Composite Score (63.9/100 BUY vs. PTGX 32.6/100 SELL), PTGX captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (58.6% vs. -58.8% operating margin) and revenue trajectory (+5723.6% vs. +54.9% YoY). Technical & Structure Timing Caution: IONS is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 23.7); meanwhile PTGX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

PTGX leads the Growth & Scale pillar: IONS posts +54.9% YoY revenue growth and -43.7% YoY earnings growth on $960M TTM revenue (3.0% gross margin, -58.8% operating margin), compared with PTGX at +5723.6% YoY revenue growth and +351.3% YoY earnings growth on $552M TTM revenue (99.8% gross margin, 58.6% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), IONS cumulative revenue shifted +56.7% while PTGX shifted +66.7%. In operating R&D and SG&A reinvestment, IONS deploys 61.8% of Rev ($593M) (0 90-day corporate R&D disclosures) versus 41.2% of Rev ($227M) (0 disclosures) for PTGX.

PTGX screens cheaper on headline valuation multiples. IONS trades at 90.9x Forward P/E, 90.9x Trailing P/E, N/M PEG, and 6.2x EV/Revenue (-64.9% FCF margin), whereas PTGX trades at 36.9x Forward P/E, 28.1x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (19.8% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IONS (-108.0% ROE) versus PTGX (39.6% ROE) capital efficiency.

In options market volatility and institutional positioning, IONS carries 59.9% implied volatility (17th %ile, Compressed (<25th %ile)), a 1.81x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (0.18β · 86% Vol realized risk). By comparison, PTGX carries 39.4% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a CONSOLIDATION options structure phase (1.02β · 35% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.